Emergence of SARS-CoV-2 Omicron variant and strategies for tackling the infection

被引:13
作者
Wu, Yan [1 ]
Long, Yiyin [2 ]
Wang, Feng [3 ]
Liu, Wei [4 ]
Wang, Yuliang [2 ]
机构
[1] Tianjin TEDA Hosp, Dept Clin Lab Med, Tianjin, Peoples R China
[2] Tianjin Med Univ, Tianjin Inst Urol, Hosp 2, Pingjiang Rd 23, Tianjin 300211, Peoples R China
[3] Tianjin Med Univ, Sch Basic Med Sci, Dept Genet, Tianjin, Peoples R China
[4] Tianjin Univ, Tianjin Childrens Hosp, Childrens Hosp, Longyan Rd 238, Tianjin 300134, Peoples R China
基金
中国国家自然科学基金;
关键词
mutations; Omicron; severe acute respiratory syndrome coronavirus 2; transmissibility; vaccination; SCIENTISTS KNOW; CHINA; MUNICIPALITY; PROVINCE;
D O I
10.1002/iid3.733
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Introduction: Nowadays, emerging SARS-CoV-2 Omicron, the novel highly mutated VOC, has quickly spread as the dominant variant in over 190 countries worldwide through the first part of 2022, which is influencing the infectivity, transmissibility, pathogenicity, and severity of COVID-19 pandemic. Additionally, clinical cases and experimental studies have reported that Omicron variant likely leads to weakened immune protection elicited by infection, antibody therapies, and vaccines. The new wave, from late February, 2022, was escalated abruptly by higher levels of transmission of Omicron BA.2 sublineage in China. Methods and Results: Following a systematic database search, this review summarizes the salient features of Omicron sublineages, and their impact on transmissibility, disease severity as well as the efficacy of the available vaccines and treatment against the Omicron. Conclusion: We hope this study will provide a scientific reference for alleviating the burden of COVID-19.
引用
收藏
页数:10
相关论文
共 82 条
[1]   Tixagevimab and Cilgavimab (Evusheld) for Pre-Exposure Prophylaxis of COVID-19 [J].
Abramowicz, Mark .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2022, 327 (04) :384-385
[2]   WILL OMICRON END THE PANDEMIC? HERE'S WHAT EXPERTS SAY [J].
Adam, David .
NATURE, 2022, 602 (7895) :20-21
[3]   Antibody evasion of SARS-CoV-2 Omicron BA.1, BA.1.1, BA.2, and BA.3 sub-lineages [J].
Ai, Jingwen ;
Wang, Xun ;
He, Xinyi ;
Zhao, Xiaoyu ;
Zhang, Yi ;
Jiang, Yuchao ;
Li, Minghui ;
Cui, Yuchen ;
Chen, Yanjia ;
Qiao, Rui ;
Li, Lin ;
Yang, Lulu ;
Li, Yi ;
Hu, Zixin ;
Zhang, Wenhong ;
Wang, Pengfei .
CELL HOST & MICROBE, 2022, 30 (08) :1077-+
[4]   Breakthrough infections after COVID-19 vaccination: Insights, perspectives and challenges [J].
Amanatidou, Evropi ;
Gkiouliava, Anna ;
Pella, Eva ;
Serafidi, Maria ;
Tsilingiris, Dimitrios ;
Vallianou, Natalia G. ;
Karampela, I. rene ;
Dalamaga, Maria .
METABOLISM OPEN, 2022, 14
[5]   Update to living WHO guideline on drugs for covid-19 [J].
不详 .
BMJ-BRITISH MEDICAL JOURNAL, 2022, 376
[6]  
[Anonymous], COVID Data Tracker: COVID-19 Vaccinations in the United States
[7]   SARS-CoV-2 Omicron variant causes mild pathology in the upper and lower respiratory tract of hamsters [J].
Armando, Federico ;
Beythien, Georg ;
Kaiser, Franziska K. ;
Allnoch, Lisa ;
Heydemann, Laura ;
Rosiak, Malgorzata ;
Becker, Svenja ;
Gonzalez-Hernandez, Mariana ;
Lamers, Mart M. ;
Haagmans, Bart L. ;
Guilfoyle, Kate ;
van Amerongen, Geert ;
Ciurkiewicz, Malgorzata ;
Osterhaus, Albert D. M. E. ;
Baumgaertner, Wolfgang .
NATURE COMMUNICATIONS, 2022, 13 (01)
[8]   Comparable neutralisation evasion of SARS-CoV-2 omicron subvariants BA.1, BA.2, and BA.3 [J].
Arora, Prerna ;
Zhang, Lu ;
Rocha, Cheila ;
Sidarovich, Anzhalika ;
Kempf, Amy ;
Schulz, Sebastian ;
Cossmann, Anne ;
Manger, Bernhard ;
Baier, Eva ;
Tampe, Bjoern ;
Moerer, Onnen ;
Dickel, Steffen ;
Dopfer-Jablonka, Alexandra ;
Jaeck, Hans-Martin ;
Behrens, Georg M. N. ;
Winkler, Martin S. ;
Poehlmann, Stefan ;
Hoffmann, Markus .
LANCET INFECTIOUS DISEASES, 2022, 22 (06) :766-767
[9]   Optimizing the dynamic zero-COVID policy in China [J].
Bai, Wei ;
Sha, Sha ;
Cheung, Teris ;
Su, Zhaohui ;
Jackson, Todd ;
Xiang, Yu-Tao .
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES, 2022, 18 (14) :5314-5316
[10]   Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study [J].
Barda, Noam ;
Dagan, Noa ;
Cohen, Cyrille ;
Hernan, Miguel A. ;
Lipsitch, Marc ;
Kohane, Isaac S. ;
Reis, Ben Y. ;
Balicer, Ran D. .
LANCET, 2021, 398 (10316) :2093-2100